You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 11, November 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tumor Necrosis Factor and Chemotherapeutic Agents

Potentiation of Cytotoxicity With Interferon Gamma

Douglas E. Dawson, MD; Markus Gapany, MD; Robert C. Burgess, MD; Peter V. Boesen, MD; Don B. Headley, MD

Arch Otolaryngol Head Neck Surg. 1992;118(11):1168-1171.


Abstract

• This study examined combinations of the recombinant human cytokines, tumor necrosis factor {alpha} and interferon gamma, with doxorubicin and dactinomycin as well as other drugs on six squamous cell carcinoma cell lines of head and neck origin using the 3(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide proliferation assay. Interferon gamma significantly enhanced the cytotoxicity of tumor necrosis factor a with dactinomycin on all six cell lines investigated, while in four of six cell lines the cytotoxicity of tumor necrosis factor {alpha} with doxorubicin was significantly augmented by interferon gamma. Additional experiments showed no effect with either cytokine in combination with cisplatin, fluorouracil, methotrexate, or etoposide. These data demonstrate that human recombinant cytokines in concert with certain drugs improve in vitro cytotoxicity and may have a potential for improving in vivo therapy.

(Arch Otolaryngol Head Neck Surg. 1992;118:1168-1171)



Author Affiliations

From the Otologic Medical Services of Iowa City (Iowa) (Dr Dawson), and the Department of Otolaryngology Head and Neck Surgery (Drs Gapany, Burgess, Boesen, and Headley), University of Iowa Hospitals and Clinics, Iowa City.


Footnotes

Accepted for publication July 10, 1992.

Reprint requests to 540 E Jefferson St, Suite 401, Iowa City, IA 52245 (Dr Dawson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Development of Head and Neck Squamous Cell Carcinoma Is Associated With Altered Cytokine Responsiveness
Douglas et al.
Mol Cancer Res 2004;2:585-593.
ABSTRACT | FULL TEXT  

Apoptotic Inhibition of Head and Neck Squamous Cell Carcinoma Cells by Tumor Necrosis Factor {alpha}
Briskin et al.
Arch Otolaryngol Head Neck Surg 1996;122:559-563.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.